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1326Reply to: ‘‘May sarcopenia and/or hepatic encephalopathy
improve the predictivity of model for end-stage liver disease?’’
and ‘‘Has the time come for using MELD-Sarcopenia score?’’sensus regarding cut-off values is of importance and that we
should continue to optimize diagnosis of sarcopenia as assessed
by CT. Yet, we believe that the optimization of prognostic mod-
els is an ongoing process and that opportunistic CT evaluation of
skeletal muscle mass could help.
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We would like to thank Lucidi et al.1 and De et al.2 for their
interest in our work3 and for highlighting some challenging
issues regarding the impact of low skeletal muscle mass in liver
transplant candidates with cirrhosis.
De et al.2 raised the valid concern that the use of body mass
index (BMI) specific cut-off values as proposed by Martin et al.4
although currently most frequently used, may have led to mis-
classification of sarcopenia in cirrhotic patients with ascites.
Ideally, BMI should be calculated based on the dry weight and
classified according to, for example, the method of Campillo
et al. that corrects for the presence and the stage of ascites.5
However, inherent to the retrospective nature of our study,
we were unable to apply this method. Nevertheless, we re-eval-
uated our data and concluded that only 28 male patients (4.8%
of the total study population) might have been wrongly classi-
fied as having sarcopenia, while they had a BMI between 25
and 27 (which could have been overestimated due to the pres-
ence of ascites) and a skeletal muscle index ranging from 43 to
53 cm2/m2. Therefore, we believe that this small fraction may
have had only minor influence on the study results if any at all.
Indeed, a cut-off value that can be employed in the general
population and is more broadly applicable across different
patient populations, is highly warranted. Recently, such values
have been proposed, although they have yet to be validated.6
Therefore, we did apply a cut-off developed for patients with
liver cirrhosis specifically by Carey et al.7 to test the robustness
of our data. The application of these cut-offs resulted in a poor
discriminative performance after correcting for model for end-
stage liver disease (MELD) score, which is not surprising, as
the MELD-score alone is used as allocation tool on the waiting
list because of its strong predictive value. In addition, waiting
list placement, disease severity, and prioritization for transplan-
tation on the one hand and skeletal muscle mass on the other
hand are all strongly correlated with the MELD score. Alto-
gether, developing a model that significantly improves the pre-
dictive value of the MELD, with an excellent concordance index
(0.839 in our cohort), remains challenging in an era in which
this model is already used to select and prioritize patients.
We agree with Lucidi et al.1 that, ideally, our results should
be externally validated, particularly in patients with low
MELD-scores who are often not listed for liver transplantation.
Our findings in this specific subgroup imply that these patients
may be under-prioritized in the current allocation system.
Therefore, analysis of the association between skeletal muscle
mass and survival of patients with liver cirrhosis who are not
listed for transplantation yet, is certainly of interest. But again,
such an unselected cohort is hard to identify retrospectively.
Lastly, the MELD score alone is an easy-to-obtain and readily
available bedside tool indeed and the addition of CT-evaluation
is more labor-intensive and not always readily available. Never-
theless, the majority of listed patients do have computed
tomography (CT) images available, as a consequence of thelantation screening protocol. We acknowledge that con- E-mail address: j.l.a.vanvugt@erasmusmc.nl
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